IL‐17 enhances the susceptibility of U‐2 OS osteosarcoma cells to NK cell lysis
SUMMARY We investigated the effect of the proinflammatory cytokine interleukin 17 (IL‐17) on the lysis of osteosarcoma cells by human NK cells. NK cells and U‐2 OS, MG‐63, HOS osteosarcoma cell lines express the IL‐17 receptor, the highest amount being found on U‐2 OS. Pre‐incubation of NK cells wit...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental immunology 2003-09, Vol.133 (3), p.344-349 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 349 |
|---|---|
| container_issue | 3 |
| container_start_page | 344 |
| container_title | Clinical and experimental immunology |
| container_volume | 133 |
| creator | HONORATI, M. C. NERI, S. CATTINI, L. FACCHINI, A. |
| description | SUMMARY
We investigated the effect of the proinflammatory cytokine interleukin 17 (IL‐17) on the lysis of osteosarcoma cells by human NK cells. NK cells and U‐2 OS, MG‐63, HOS osteosarcoma cell lines express the IL‐17 receptor, the highest amount being found on U‐2 OS. Pre‐incubation of NK cells with IL‐17 did not affect the cytotoxicity against osteosarcomas, that was increased when U‐2 OS were pre‐incubated with IL‐17. In IL‐17 treated U‐2 OS osteosarcoma cells FACS analysis demonstrated an increased expression of fibronectin among the panel of adhesion molecules assayed, and the treatment with anti‐fibronectin antibodies decreased the NK cytotoxicity. The comparison between interferon gamma (IFN‐γ) treated and IFN‐γ/IL‐17‐treated U‐2 OS showed a decreased susceptibility to NK lysis associated with a reduced expression of CD49f on U‐2 OS treated with IFN‐γ/IL‐17. IL‐17 appears to be a modulator of NK adhesion molecules on U‐2 OS cells but antagonizes with IFN‐γ on NK lysis. |
| doi_str_mv | 10.1046/j.1365-2249.2003.02234.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1808781</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18937760</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4734-b09346203260a5dbd86515c0831aec41797085d16e11900d03fe41bfc16c7a2a3</originalsourceid><addsrcrecordid>eNqNkc9u1DAQhy1ERbeFV0AWEtySjv_Ejg8gVasWVqzaQ-nZchyH9SobL3EC3RuPwDPyJDjdVUs5cfJY8_1GM_oQwgRyAlycrXPCRJFRylVOAVgOlDKe3z1Ds4fGczQDAJWplDhGJzGu01cIQV-gY0IVA1aoGbpZLH___EUkdt3KdNZFPKwcjmO0bjv4yrd-2OHQ4NtEUXx9g0McXIimt2FjsHVtmxIBX32-r3G7iz6-REeNaaN7dXhP0e3lxZf5p2x5_XExP19mlkvGswoU44ICowJMUVd1KQpSWCgZMc5yIpWEsqiJcIQogBpY4zipGkuElYYadoo-7Odux2rjauu6oTet3vZ-Y_qdDsbrp53Or_TX8F2TEkpZkjTg3WFAH76NLg564-N0h-lcGGPiFJNSQALf_AOuw9h36ThNlCh5KQlNULmHbB9i7F3zsAkBPWnTaz3Z0ZMdPWnT99r0XYq-_vuSx-DBUwLeHgATrWmbPrny8ZErgBe0kIl7v-d--Nbt_nsBPb9YTBX7A2mHsx8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>196848712</pqid></control><display><type>article</type><title>IL‐17 enhances the susceptibility of U‐2 OS osteosarcoma cells to NK cell lysis</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>HONORATI, M. C. ; NERI, S. ; CATTINI, L. ; FACCHINI, A.</creator><creatorcontrib>HONORATI, M. C. ; NERI, S. ; CATTINI, L. ; FACCHINI, A.</creatorcontrib><description>SUMMARY
We investigated the effect of the proinflammatory cytokine interleukin 17 (IL‐17) on the lysis of osteosarcoma cells by human NK cells. NK cells and U‐2 OS, MG‐63, HOS osteosarcoma cell lines express the IL‐17 receptor, the highest amount being found on U‐2 OS. Pre‐incubation of NK cells with IL‐17 did not affect the cytotoxicity against osteosarcomas, that was increased when U‐2 OS were pre‐incubated with IL‐17. In IL‐17 treated U‐2 OS osteosarcoma cells FACS analysis demonstrated an increased expression of fibronectin among the panel of adhesion molecules assayed, and the treatment with anti‐fibronectin antibodies decreased the NK cytotoxicity. The comparison between interferon gamma (IFN‐γ) treated and IFN‐γ/IL‐17‐treated U‐2 OS showed a decreased susceptibility to NK lysis associated with a reduced expression of CD49f on U‐2 OS treated with IFN‐γ/IL‐17. IL‐17 appears to be a modulator of NK adhesion molecules on U‐2 OS cells but antagonizes with IFN‐γ on NK lysis.</description><identifier>ISSN: 0009-9104</identifier><identifier>EISSN: 1365-2249</identifier><identifier>DOI: 10.1046/j.1365-2249.2003.02234.x</identifier><identifier>PMID: 12930359</identifier><identifier>CODEN: CEXIAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>adhesion molecules ; Adult ; Basic Immunology ; Biological and medical sciences ; Bone Neoplasms - immunology ; Bone Neoplasms - metabolism ; Cytotoxicity Tests, Immunologic ; Diseases of the osteoarticular system ; Fibronectins - metabolism ; Flow Cytometry ; Humans ; IL‐17 ; Integrin alpha2 - metabolism ; Integrin alpha6 - metabolism ; Interferon-gamma - therapeutic use ; Interleukin-17 - therapeutic use ; Killer Cells, Natural - immunology ; Medical sciences ; NK activity ; osteosarcoma ; Osteosarcoma - immunology ; Osteosarcoma - metabolism ; Receptors, Interleukin - analysis ; Receptors, Interleukin-17 ; Recombinant Proteins - analysis ; Stimulation, Chemical ; Tumor Cells, Cultured ; Tumors of striated muscle and skeleton</subject><ispartof>Clinical and experimental immunology, 2003-09, Vol.133 (3), p.344-349</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Sep 2003</rights><rights>2003 Blackwell Publishing Ltd 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4734-b09346203260a5dbd86515c0831aec41797085d16e11900d03fe41bfc16c7a2a3</citedby><cites>FETCH-LOGICAL-c4734-b09346203260a5dbd86515c0831aec41797085d16e11900d03fe41bfc16c7a2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808781/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808781/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15045257$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12930359$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HONORATI, M. C.</creatorcontrib><creatorcontrib>NERI, S.</creatorcontrib><creatorcontrib>CATTINI, L.</creatorcontrib><creatorcontrib>FACCHINI, A.</creatorcontrib><title>IL‐17 enhances the susceptibility of U‐2 OS osteosarcoma cells to NK cell lysis</title><title>Clinical and experimental immunology</title><addtitle>Clin Exp Immunol</addtitle><description>SUMMARY
We investigated the effect of the proinflammatory cytokine interleukin 17 (IL‐17) on the lysis of osteosarcoma cells by human NK cells. NK cells and U‐2 OS, MG‐63, HOS osteosarcoma cell lines express the IL‐17 receptor, the highest amount being found on U‐2 OS. Pre‐incubation of NK cells with IL‐17 did not affect the cytotoxicity against osteosarcomas, that was increased when U‐2 OS were pre‐incubated with IL‐17. In IL‐17 treated U‐2 OS osteosarcoma cells FACS analysis demonstrated an increased expression of fibronectin among the panel of adhesion molecules assayed, and the treatment with anti‐fibronectin antibodies decreased the NK cytotoxicity. The comparison between interferon gamma (IFN‐γ) treated and IFN‐γ/IL‐17‐treated U‐2 OS showed a decreased susceptibility to NK lysis associated with a reduced expression of CD49f on U‐2 OS treated with IFN‐γ/IL‐17. IL‐17 appears to be a modulator of NK adhesion molecules on U‐2 OS cells but antagonizes with IFN‐γ on NK lysis.</description><subject>adhesion molecules</subject><subject>Adult</subject><subject>Basic Immunology</subject><subject>Biological and medical sciences</subject><subject>Bone Neoplasms - immunology</subject><subject>Bone Neoplasms - metabolism</subject><subject>Cytotoxicity Tests, Immunologic</subject><subject>Diseases of the osteoarticular system</subject><subject>Fibronectins - metabolism</subject><subject>Flow Cytometry</subject><subject>Humans</subject><subject>IL‐17</subject><subject>Integrin alpha2 - metabolism</subject><subject>Integrin alpha6 - metabolism</subject><subject>Interferon-gamma - therapeutic use</subject><subject>Interleukin-17 - therapeutic use</subject><subject>Killer Cells, Natural - immunology</subject><subject>Medical sciences</subject><subject>NK activity</subject><subject>osteosarcoma</subject><subject>Osteosarcoma - immunology</subject><subject>Osteosarcoma - metabolism</subject><subject>Receptors, Interleukin - analysis</subject><subject>Receptors, Interleukin-17</subject><subject>Recombinant Proteins - analysis</subject><subject>Stimulation, Chemical</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors of striated muscle and skeleton</subject><issn>0009-9104</issn><issn>1365-2249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9u1DAQhy1ERbeFV0AWEtySjv_Ejg8gVasWVqzaQ-nZchyH9SobL3EC3RuPwDPyJDjdVUs5cfJY8_1GM_oQwgRyAlycrXPCRJFRylVOAVgOlDKe3z1Ds4fGczQDAJWplDhGJzGu01cIQV-gY0IVA1aoGbpZLH___EUkdt3KdNZFPKwcjmO0bjv4yrd-2OHQ4NtEUXx9g0McXIimt2FjsHVtmxIBX32-r3G7iz6-REeNaaN7dXhP0e3lxZf5p2x5_XExP19mlkvGswoU44ICowJMUVd1KQpSWCgZMc5yIpWEsqiJcIQogBpY4zipGkuElYYadoo-7Odux2rjauu6oTet3vZ-Y_qdDsbrp53Or_TX8F2TEkpZkjTg3WFAH76NLg564-N0h-lcGGPiFJNSQALf_AOuw9h36ThNlCh5KQlNULmHbB9i7F3zsAkBPWnTaz3Z0ZMdPWnT99r0XYq-_vuSx-DBUwLeHgATrWmbPrny8ZErgBe0kIl7v-d--Nbt_nsBPb9YTBX7A2mHsx8</recordid><startdate>200309</startdate><enddate>200309</enddate><creator>HONORATI, M. C.</creator><creator>NERI, S.</creator><creator>CATTINI, L.</creator><creator>FACCHINI, A.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Oxford University Press</general><general>Blackwell Science Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>5PM</scope></search><sort><creationdate>200309</creationdate><title>IL‐17 enhances the susceptibility of U‐2 OS osteosarcoma cells to NK cell lysis</title><author>HONORATI, M. C. ; NERI, S. ; CATTINI, L. ; FACCHINI, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4734-b09346203260a5dbd86515c0831aec41797085d16e11900d03fe41bfc16c7a2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>adhesion molecules</topic><topic>Adult</topic><topic>Basic Immunology</topic><topic>Biological and medical sciences</topic><topic>Bone Neoplasms - immunology</topic><topic>Bone Neoplasms - metabolism</topic><topic>Cytotoxicity Tests, Immunologic</topic><topic>Diseases of the osteoarticular system</topic><topic>Fibronectins - metabolism</topic><topic>Flow Cytometry</topic><topic>Humans</topic><topic>IL‐17</topic><topic>Integrin alpha2 - metabolism</topic><topic>Integrin alpha6 - metabolism</topic><topic>Interferon-gamma - therapeutic use</topic><topic>Interleukin-17 - therapeutic use</topic><topic>Killer Cells, Natural - immunology</topic><topic>Medical sciences</topic><topic>NK activity</topic><topic>osteosarcoma</topic><topic>Osteosarcoma - immunology</topic><topic>Osteosarcoma - metabolism</topic><topic>Receptors, Interleukin - analysis</topic><topic>Receptors, Interleukin-17</topic><topic>Recombinant Proteins - analysis</topic><topic>Stimulation, Chemical</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors of striated muscle and skeleton</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HONORATI, M. C.</creatorcontrib><creatorcontrib>NERI, S.</creatorcontrib><creatorcontrib>CATTINI, L.</creatorcontrib><creatorcontrib>FACCHINI, A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and experimental immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HONORATI, M. C.</au><au>NERI, S.</au><au>CATTINI, L.</au><au>FACCHINI, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IL‐17 enhances the susceptibility of U‐2 OS osteosarcoma cells to NK cell lysis</atitle><jtitle>Clinical and experimental immunology</jtitle><addtitle>Clin Exp Immunol</addtitle><date>2003-09</date><risdate>2003</risdate><volume>133</volume><issue>3</issue><spage>344</spage><epage>349</epage><pages>344-349</pages><issn>0009-9104</issn><eissn>1365-2249</eissn><coden>CEXIAL</coden><abstract>SUMMARY
We investigated the effect of the proinflammatory cytokine interleukin 17 (IL‐17) on the lysis of osteosarcoma cells by human NK cells. NK cells and U‐2 OS, MG‐63, HOS osteosarcoma cell lines express the IL‐17 receptor, the highest amount being found on U‐2 OS. Pre‐incubation of NK cells with IL‐17 did not affect the cytotoxicity against osteosarcomas, that was increased when U‐2 OS were pre‐incubated with IL‐17. In IL‐17 treated U‐2 OS osteosarcoma cells FACS analysis demonstrated an increased expression of fibronectin among the panel of adhesion molecules assayed, and the treatment with anti‐fibronectin antibodies decreased the NK cytotoxicity. The comparison between interferon gamma (IFN‐γ) treated and IFN‐γ/IL‐17‐treated U‐2 OS showed a decreased susceptibility to NK lysis associated with a reduced expression of CD49f on U‐2 OS treated with IFN‐γ/IL‐17. IL‐17 appears to be a modulator of NK adhesion molecules on U‐2 OS cells but antagonizes with IFN‐γ on NK lysis.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>12930359</pmid><doi>10.1046/j.1365-2249.2003.02234.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9104 |
| ispartof | Clinical and experimental immunology, 2003-09, Vol.133 (3), p.344-349 |
| issn | 0009-9104 1365-2249 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1808781 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | adhesion molecules Adult Basic Immunology Biological and medical sciences Bone Neoplasms - immunology Bone Neoplasms - metabolism Cytotoxicity Tests, Immunologic Diseases of the osteoarticular system Fibronectins - metabolism Flow Cytometry Humans IL‐17 Integrin alpha2 - metabolism Integrin alpha6 - metabolism Interferon-gamma - therapeutic use Interleukin-17 - therapeutic use Killer Cells, Natural - immunology Medical sciences NK activity osteosarcoma Osteosarcoma - immunology Osteosarcoma - metabolism Receptors, Interleukin - analysis Receptors, Interleukin-17 Recombinant Proteins - analysis Stimulation, Chemical Tumor Cells, Cultured Tumors of striated muscle and skeleton |
| title | IL‐17 enhances the susceptibility of U‐2 OS osteosarcoma cells to NK cell lysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T19%3A47%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IL%E2%80%9017%20enhances%20the%20susceptibility%20of%20U%E2%80%902%20OS%20osteosarcoma%20cells%20to%20NK%20cell%20lysis&rft.jtitle=Clinical%20and%20experimental%20immunology&rft.au=HONORATI,%20M.%20C.&rft.date=2003-09&rft.volume=133&rft.issue=3&rft.spage=344&rft.epage=349&rft.pages=344-349&rft.issn=0009-9104&rft.eissn=1365-2249&rft.coden=CEXIAL&rft_id=info:doi/10.1046/j.1365-2249.2003.02234.x&rft_dat=%3Cproquest_pubme%3E18937760%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=196848712&rft_id=info:pmid/12930359&rfr_iscdi=true |